Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Q2 Medicine
Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-06-26 DOI:10.12997/jla.2025.14.1.5
Fernando Bril, Gabriela Berg, Magali Barchuk, Juan Patricio Nogueira
{"title":"Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Fernando Bril, Gabriela Berg, Magali Barchuk, Juan Patricio Nogueira","doi":"10.12997/jla.2025.14.1.5","DOIUrl":null,"url":null,"abstract":"<p><p>Dyslipidemia is a major risk factor for cardiovascular disease, and its impact may be exacerbated when accompanied by metabolic dysfunction-associated steatotic liver disease (MASLD). The simultaneous management of these conditions poses multiple challenges for healthcare providers. Insulin resistance has been implicated in the pathogenesis of both dyslipidemia and MASLD, necessitating a holistic approach to managing dyslipidemia, glucose levels, body weight, and MASLD. This review explores the intricate pathophysiological relationship between MASLD and dyslipidemia. It also examines current guidance regarding the use of lipid-lowering agents (including statins, ezetimibe, fibrates, omega-3 polyunsaturated fatty acids, and proprotein convertase subtilisin/kexin type 9 inhibitors) as well as glucose-lowering medications (such as pioglitazone, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors) in patients with MASLD, with or without metabolic dysfunction-associated steatohepatitis (MASH), and dyslipidemia. Additionally, the review addresses the potential of emerging drugs to concurrently target both MASLD/MASH and dyslipidemia. Our hope is that a deeper understanding of the mechanisms underlying MASLD and dyslipidemia may assist clinicians in the management of these complex cases.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"5-29"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791423/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Lipid and Atherosclerosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12997/jla.2025.14.1.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Dyslipidemia is a major risk factor for cardiovascular disease, and its impact may be exacerbated when accompanied by metabolic dysfunction-associated steatotic liver disease (MASLD). The simultaneous management of these conditions poses multiple challenges for healthcare providers. Insulin resistance has been implicated in the pathogenesis of both dyslipidemia and MASLD, necessitating a holistic approach to managing dyslipidemia, glucose levels, body weight, and MASLD. This review explores the intricate pathophysiological relationship between MASLD and dyslipidemia. It also examines current guidance regarding the use of lipid-lowering agents (including statins, ezetimibe, fibrates, omega-3 polyunsaturated fatty acids, and proprotein convertase subtilisin/kexin type 9 inhibitors) as well as glucose-lowering medications (such as pioglitazone, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors) in patients with MASLD, with or without metabolic dysfunction-associated steatohepatitis (MASH), and dyslipidemia. Additionally, the review addresses the potential of emerging drugs to concurrently target both MASLD/MASH and dyslipidemia. Our hope is that a deeper understanding of the mechanisms underlying MASLD and dyslipidemia may assist clinicians in the management of these complex cases.

管理代谢功能障碍相关脂肪变性肝病患者血脂异常的实用方法
血脂异常是心血管疾病的主要危险因素,当伴有代谢功能障碍相关的脂肪变性肝病(MASLD)时,其影响可能会加剧。同时管理这些条件对医疗保健提供者提出了多重挑战。胰岛素抵抗与血脂异常和MASLD的发病机制有关,因此需要采用整体方法来管理血脂异常、血糖水平、体重和MASLD。本文综述了MASLD与血脂异常之间复杂的病理生理关系。它还检查了目前关于MASLD患者使用降脂剂(包括他汀类药物、依折替米贝、贝特类药物、omega-3多不饱和脂肪酸和蛋白转化酶枯草菌素/酮素9型抑制剂)以及降血糖药物(如吡格列酮、胰高血糖素样肽-1受体激动剂和钠-葡萄糖共转运蛋白2抑制剂)的指南,伴有或不伴有代谢功能障碍相关脂肪性肝炎(MASH)和血脂异常。此外,该综述还探讨了同时针对MASLD/MASH和血脂异常的新兴药物的潜力。我们希望对MASLD和血脂异常的机制有更深入的了解,可以帮助临床医生管理这些复杂的病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Lipid and Atherosclerosis
Journal of Lipid and Atherosclerosis Medicine-Internal Medicine
CiteScore
6.90
自引率
0.00%
发文量
26
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信